Antidepressants as first-line agents in the current pharmacotherapy of anxiety disorders

Professional Psychology: Research and Practice

Volumn 32, Issue 1, 2001, Pages 101-104

  Rivas Vazquez, Rafael A ^a  

^a Neurologic Center of South Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0035530708     PISSN: 07357028     EISSN: None     Source Type: Journal    
DOI: 10.1037/0735-7028.32.1.101     Document Type: Review

References (34)

1. Altamura, A. C., Pioloi, R., Vitto, M., & Mannu, P. (1999). Venlafaxine in social phobia: A study in selective serotonin reuptake inhibitor non-responders. International Journal of Clinical Psychopharmacology, 14, 239-245.
2. Bakker, A., van Dyck, R., Spinhoven, P., & van Balkom, J. L. M. (1999). Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. Journal of Clinical Psychiatry, 60, 831-838.
3. Black, D. W., Wesner, R., Bowers, W., & Gabel, J. (1993). A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Archives of General Psychiatry, 50, 44-50.
4. Brady, K., Pearlstein, T., Asnis, G. M., Baker, D., Rothbaum, B., Sikes, C. R., & Farfel, G. M. (2000). Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial. JAMA, 283, 1837-1844.
5. Connor, K. M., Davidson, J. R., Weisler, R. H., & Ahearn, E. (1999). A pilot study of mirtazapine in post-traumatic stress disorder. International Journal of Clinical Psychopharmacology, 14, 29-31.
6. Davidson, J. R. T., DuPont, R. L., Hedges, D., & Haskins, T. (1999). Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Journal of Clinical Psychiatry, 60, 528-535.
7. Davis, M. (1992). The role of the amygdala in fear-potentiated startle: Implications for animal models of anxiety. Trends in Pharmacological Sciences, 13, 35-41.
8. DeMartinis, N. A., Schweizer, E., & Rickels, K. (1996). An open-label trial of nefazodone in high comorbidity panic disorder. Journal of Clinical Psychiatry, 57, 245-248.
9. Emmanuel, N. P., Ware, M. R., Brawman-Mintzer, O., Ballenger, J. C., & Lydiard, R. B. (1999). Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. Journal of Clinical Psychiatry, 60, 299-301.
10. Expert Consensus Guideline Series. (1999). Guideline 4: Selecting the initial medication. Journal of Clinical Psychiatry, 60(Suppl. 16), 18-23.
11. Feighner, J. P. (1999). Overview of antidepressants currently used to treat anxiety disorders. Journal of Clinical Psychiatry, 60(Suppl. 22), 18-22.
12. Goodman, W. K. (1999). Obsessive-compulsive disorder: Diagnosis and treatment. Journal of Clinical Psychiatry, 60(Suppl. 18), 27-32.
13. German, J. M., Liebowitz, M. R., Fyer, A. J., Goetz, D., Campeas, R. B., Fyer, M. R., Davies, S. O., & Klein, D. F. (1987). An open trial of fluoxetine in the treatment of panic attacks. Journal of Clinical Psychopharmacology, 7, 329-332.
14. Greenberg, P. E., Sisitsky, T., Kessler, R. C., Finkelstein, S. N., Berndt, E. R., Davidson, J. R. T., Ballenger, J. C., & Fyer, A. J. (1999). The economic burden of anxiety disorders in the 1990s. Journal of Clinical Psychiatry, 60, 427-435.
15. Hamner, M. B., & Frueh, B. C. (1998). Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post-traumatic stress disorder. International Journal of Clinical Psychopharmacology, 13, 233-234.
16. Hidalgo, R., Hertzberg, M. A., Mellman, T., Petty, F., Tucker, P., Weisler, R., Zisook, S., Chen, S., Churchill, E., & Davidson, J. (1999). Nefazodone in post-traumatic stress disorder: Results from six open-label trials. International Journal of Clinical Psychopharmacology, 14, 61-68.
17. Kelsey, J. E. (1995). Venlafaxine in social phobia. Psychopharmacology Bulletin, 31, 767-771.
18. Kessler, R. C., McGonagle, K., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., Wittchen, H. U., & Kendler, K. S. (1994). Lifetime and 12-month prevalence rates of DSM-III-R psychiatric disorders in the United States. Archives of General Psychiatry, 51, 8-19.
19. Lecrubier, Y., Judge, R., & the Collaborative Paroxetine Panic Study Investigators. (1997). Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatrica Scandinavia, 95, 153-160.
20. Leonard, H. L. (1997). New developments in the treatment of obsessive-compulsive disorder. Journal of Clinical Psychiatry, 58(Suppl. 14), 39-45.
21. Lepola, U. M., Wade, A. G., Leinonen, E. V., Koponen, H. J., Frazer, J., Sjödin, I., Penttinen, J. T., Pedersen, T., & Lehto, H. J. (1998). A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. Journal of Clinical Psychiatry, 59, 528-534.
22. Liebowitz, M. R. (1999). Update on the diagnosis and treatment of social anxiety disorder. Journal of Clinical Psychiatry, 60(Suppl. 18), 22-26.
23. Ninan, P. T. (1999). The functional anatomy, neurochemistry, and pharmacology of anxiety. Journal of Clinical Psychiatry, 60(Suppl. 22), 12-17.
24. Nutt, D. J. (1998). Antidepressants in panic disorder: Clinical and preclinical mechanisms. Journal of Clinical Psychiatry, 59(Suppl. 8), 24-28.
25. Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995). Paroxetine in the treatment of panic disorder: A randomised, double-blind, placebo-controlled study. British Journal of Psychiatry, 167, 374-379.
26. Papp, L. A., Schneier, F. R., Fyer, A. J., Liebowitz, M. R., Gorman, J. M., Coplan, J. D., Campeas, R., Fallon, B. A., & Klein, D. F. (1997). Clomipramine treatment of panic disorder: Pros and cons. Journal of Clinical Psychiatry, 58, 423-425.
27. Pearlstein, T. (2000). Antidepressant treatment of posttraumatic stress disorder. Journal of Clinical Psychiatry, 61(Suppl. 7), 40-43.
28. Physician's desk reference (54th ed.). (2000). Montvale, NJ: Medical Economics Data.
29. Pohl, R. B., Wolkow, R. M., & Clary, C. M. (1998). Sertraline in the treatment of panic disorder: A double-blind multicenter trial. American Journal of Psychiatry, 1998, 1189-1195.
30. Rocca, P., Fonzo, V., Scotta, M., Zanalda, E., & Ravizza, L. (1997). Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatrica Scandinavia, 95, 444-450.
31. Schatzberg, A. F. (2000). New indications for antidepressants. Journal of Clinical Psychiatry, 61(Suppl. 11), 9-17.
32. Stahl, S. M. (1999). Mergers and acquisitions among psychotropics: The antidepressants takeover of anxiety may now be complete. Journal of Clinical Psychiatry, 60, 282-283.
33. Stein, M. B., Liebowitz, M. R., Lydiard, R. B., Pitts, C. D., Bushnell, W., & Gergel, I. (1998). Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial. JAMA, 280, 708-713.
34. Zisook, S., Chentsova-Dutton, B. A., Smith-Vaniz, A., Kline, N. A., Ellenor, G. L., Kodsi, A. B., & Gillin, J. C. (2000). Nefazodone in patients with treatment-refractory posttraumatic stress disorder. Journal of Clinical Psychiatry, 61, 203-208.